In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

STORY: Novo Nordisk is ramping up lawsuits against U.S. companies selling cheaper versions of its weight-loss drug Wegovy. But one firm remains conspicuously absent: Hims & Hers.This telehealth ...

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 3.6% in the afternoon session after the ...

Consumer demand for GLP-1 drugs like Ozempic and Wegovy has drawn a flood of new entrants. Yaccarino will have to find a way ...

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Through a trust, Dudum sold about $33.4 million worth of his company’s stock on Thursday, according to a filing with the ...

Doctors suggest that anybody with a Body mass index of over 30 or greater than 27 is advised to try weight loss drugs.

Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.